Clinical Trial

Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma

Study acronym: 24CT015
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This will be a Phase 1, open-label study to evaluate the safety and efficacy of BEAM-201 in patients with R/R T-ALL or T-LLy. BEAM-201 is an allogeneic anti-CD7 CART therapy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2025-04-11; most recent amendment 2026-07-03.
Status change: Not Yet Recruiting → Recruiting 2025-04-29
Trial Details
NCT Number NCT06934382
Lead Sponsor Stephan Grupp MD PhD
Collaborators: Beam Therapeutics Inc.
Conditions T-Cell Acute Lymphoblastic Leukemia/Lymphoma
Enrollment 33 participants
Start Date 2025-04-29
Primary Completion 2029-05-30 (estimated)
Study Completion 2031-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-07